TNF-α blockers, or anti-TNF-α (aTNF-α), have been involved in the treatment of psoriasis vulgaris, rheumatoid arthritis, and inflammatory bowel disease and were recently approved for hidradenitis suppurativa. The gene discussed is TNF; the disease is hidradenitis suppurativa.